[Lipid lowering treatment of severe hypertriglyceridemia with acute pancreatitis caused by everolimus in a patient with a neuroendocrine tumor]. / Tratamiento hipolipemiante de la pancreatitis aguda secundaria a hipertrigliceridemia severa por everolimus en un paciente con tumor neuroendocrino.
An Sist Sanit Navar
; 43(1): 103-106, 2020 Apr 20.
Article
em Es
| MEDLINE
| ID: mdl-32242549
ABSTRACT
Everolimus is an mTOR inhibitor, approved as a treatment for cancer and as an immunosuppressant agent in solid organ transplantation; it frequently produces toxic metabolic effects, particularly of the most severe kind. Its use can cause hyperglycemia, hypercholesterolemia and hypertriglyceridemia; thus, metabolic values should be monitored regularly to prevent these adverse events. We present the case of a woman with an intestinal neuroendocrine tumor who developed two episodes of acute pancreatitis, secondary to severe hypertriglyceridemia caused by everolimus. After treatment with fibrates and omega-3, triglyceride levels returned to baseline, without developing new metabolic or digestive complications. Targeted levels of triglyceride for cancer patients treated with everolimus, should be below 500 or 300 mg/dL, depending on whether life expectancy is less or longer than one year, respectively.
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Pancreatite
/
Hipertrigliceridemia
/
Tumores Neuroendócrinos
/
Everolimo
/
Neoplasias do Íleo
/
Hipolipemiantes
/
Antineoplásicos
Limite:
Female
/
Humans
/
Middle aged
Idioma:
Es
Revista:
An Sist Sanit Navar
Assunto da revista:
SAUDE PUBLICA
Ano de publicação:
2020
Tipo de documento:
Article